Atea Pharmaceuticals, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2021 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Atea Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2021 to Q3 2022.
  • Atea Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2022 was $4.51M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $4.51M Sep 30, 2022 10-Q 2022-11-07
Q2 2021 $50M Jun 30, 2021 10-Q 2021-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.